Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A. Cazzaniga G, et al. Among authors: pieters r. Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27. Haematologica. 2018. PMID: 29079599 Free PMC article.
Biological and therapeutic aspects of infant leukemia.
Biondi A, Cimino G, Pieters R, Pui CH. Biondi A, et al. Among authors: pieters r. Blood. 2000 Jul 1;96(1):24-33. Blood. 2000. PMID: 10891426 Free article. Review. No abstract available.
Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?
De Haas V, Kaspers GJ, Oosten L, Bresters D, Pieters R, Van Der Velden VH, Van Wering ER, Van Den Berg H, Van Der Schoot CE. De Haas V, et al. Among authors: pieters r. Br J Haematol. 2002 Sep;118(4):1190-1. doi: 10.1046/j.1365-2141.2002.36211.x. Br J Haematol. 2002. PMID: 12199807 Free article. No abstract available.
No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities.
Moorman AV, Raimondi SC, Pui CH, Baruchel A, Biondi A, Carroll AJ, Forestier E, Gaynon PS, Harbott J, Harms DO, Heerema N, Pieters R, Schrappe M, Silverman LB, Vilmer E, Harrison CJ; Ponte di Legno Working Group. Moorman AV, et al. Among authors: pieters r. Leukemia. 2005 Apr;19(4):557-63. doi: 10.1038/sj.leu.2403695. Leukemia. 2005. PMID: 15744345
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R. Stam RW, et al. Among authors: pieters r. Blood. 2005 Oct 1;106(7):2484-90. doi: 10.1182/blood-2004-09-3667. Epub 2005 Jun 14. Blood. 2005. PMID: 15956279 Free article.
995 results